RM Primary Logo - Humble.png
Revolution Medicines to Participate in Upcoming Investor Conferences
01 févr. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
01 févr. 2024 07h30 HE | Purple Biotech Ltd.
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Research Nester Logo.jpg
Medical Tourism Market revenue to surpass USD 100 Billion by 2035, says Research Nester
29 janv. 2024 05h00 HE | Research Nester
New York, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The global medical tourism market size is expected to expand at ~12% CAGR from 2023 to 2035. The market is anticipated to garner a revenue of USD 100...
Research Nester Logo.jpg
Prefilled Syringes Market revenue to surpass USD 45 Billion by 2033, says Research Nester
25 janv. 2024 05h00 HE | Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global prefilled syringes market size is projected to expand at ~13% CAGR between 2023 and 2033.The market is expected to garner a revenue of USD 45...
Erasmus MC
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
24 janv. 2024 09h10 HE | AIM ImmunoTech Inc.
OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center...
Health
KFSH&RC Celebrates 25 Scientists Named in Stanford's Top 2% Most-Cited Researchers Worldwide
24 janv. 2024 05h16 HE | King Faisal Specialist Hospital & Research Centre
RIYADH, Saudi Arabia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them...
الصحة
"التخصصي" يكرّم 25 عالماً ضمن قائمة ستانفورد لـ 2% من العلماء الأعلى استشهاداً بأبحاثهم
24 janv. 2024 05h16 HE | King Faisal Specialist Hospital & Research Centre
الرياض, Jan. 24, 2024 (GLOBE NEWSWIRE) -- كرّم مستشفى الملك فيصل التخصصي ومركز الأبحاث 25 من علمائه، صُنّفوا ضمن قائمة جامعة ستانفورد لـ ـ2% من العلماء والباحثين الأعلى استشهادًا بأبحاثهم...
Charlie McAvoy With Waltham Fire Department
Service Credit Union Pledges to Donate $200,000 to First Responders in Campaign With Charlie McAvoy
23 janv. 2024 16h53 HE | Service Federal Credit Union
Service Credit Union has teamed up with Charlie McAvoy to donate $200,000 toward heart and cancer screenings for first responders.
erasmus_mc_cover
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
22 janv. 2024 08h55 HE | AIM ImmunoTech Inc.
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center...
BioNTech and Duality
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22 janv. 2024 06h45 HE | BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...